Medpace Holdings, Inc. MEDP Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total Revenue by Product | ||||||
| AVAI | $141.89M+5.2% | $134.94M+2.6% | $131.53M-1.4% | $133.39M-7.0% | $143.49M-8.3% | |
| Cardiology | $280.14M+9.9% | $254.84M+10.4% | $230.88M+11.3% | $207.35M+7.6% | $192.74M+5.9% | |
| Central Nervous System | $237.35M-0.8% | $239.37M+2.0% | $234.64M+1.6% | $230.98M-0.9% | $233.1M+1.1% | |
| Metabolic | $778.35M+4.1% | $747.59M+3.9% | $719.84M+4.0% | $692.12M+3.8% | $666.52M+2.3% | |
| Oncology | $834.5M+12.0% | $744.96M+20.5% | $618.01M+13.7% | $543.49M+8.3% | $501.92M+9.7% | |
| Other | $406.03M-0.6% | $408.55M-3.5% | $423.48M-0.2% | $424.45M+1.3% | $418.82M-2.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Medpace Holdings, Inc. break its business down?
- Medpace Holdings, Inc. (MEDP) reports total revenue by product across 6 parts — AVAI, Cardiology, Central Nervous System, Metabolic and Oncology. Each is extracted from the segment footnotes and tracked over time.
- Where does Medpace Holdings, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Medpace Holdings, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
